Etiologic agents and extended-spectrum beta-lactamase production in urinary tract infections in Sanandaj, Iran

Abstract

Abstract. Extended-spectrum β-lactamases has emerged as an important mechanism of resistance in Gram-negative bacteria. In this study, we aimed to determine the frequency of extended spectrum beta lactamase  producing isolates in (urinary tract infections). ESBL-production was tested by the double-disc synergy method and more confirmed by PCR amplification. Out of 188 isolated microorganisms Escherichia coli (80%) was the most frequent. Production was determined in 14.5% of clinically gram negative isolates. CTX-M type was the most prevalent type (12.7%) and SHV and TEM type were in the next ranks. Our data indicate the spread of these enzymes in clinically gram negative isolates in urinary tract samples collected from two general hospitals of Sanandaj.

Key words: Urinary tract infections; extended-spectrum βeta-lactamase; Escherichia coli

Keywords

• -

Kaynakça

1. Ko KS, Suh JY, Peck KR, et al. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood. Diagn Microbiol Infect Dis 2007; 58: 111-115.
2. Hoepelman AI, Meiland R, Geerlings SE. Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus. Int J Antimicrob Agents 2003; 22 Suppl 2: 35-43.
3. Ramazanzadeh R, Chitsaz M, Bahmani N. Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing bacteria in intensive care units of Sanandaj general hospitals (Kurdistan, Iran). Chemotherapy 2009; 55: 287-292.
4. Arpin C, Dubois V, Coulange L, et al. Extended- spectrum beta-lactamase-producing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother 2003; 47: 3506-3514.
5. Borer A, Gilad J, Menashe G, Peled N, Riesenberg K, Schlaeffer F. Extended-spectrum beta-lactamase-producing Enterobacteriaceae strains in community-acquired bacteremia in Southern Israel. Med Sci Monit 2002; 8: CR44- CR47.
6. Minarini LA, Gales AC, Palazzo IC, Darini AL. Prevalence of community-occurring extended spectrum beta-lactamase-producing Enterobacteriaceae in Brazil. Curr Microbiol 2007; 54: 335-341.
7. Moubareck C, Daoud Z, Hakimé NI, et al. Countrywide spread of community- and hospital- acquired extended-spectrum beta-lactamase (CTX-M-15)-producing Enterobacteriaceae in Lebanon. J Clin Microbiol 2005; 43: 3309-3313.
8. Jain S, Andrews J, Fraise A, Brenwald N. Rapid detection of extended-spectrum beta-lactamase- producing Gram-negative bacilli in blood cultures. J Antimicrob Chemother 2007; 60: 652-654.

9. Mirsalehian A, Feizabadi M, Nakhjavani FA, Jabalameli F, Goli H, Kalantari N. Detection of VEB-1, OXA-10 and PER-1 genotypes in extended-spectrum beta-lactamase-producing Pseudomonas aeruginosa strains isolated from burn patients. Burns 2010; 36: 70-74.
10. Bazzaz BS, Naderinasab M, Mohamadpoor AH, Farshadzadeh Z, Ahmadi S, Yousefi F. The prevalence of extended-spectrum beta-lactamase- producing Escherichia coli and Klebsiella pneumoniae among clinical isolates from a general hospital in Iran. Acta Microbiol Immunol Hung 2009; 56: 89-99.
11. Bahar MA, Jamali S, Samadikuchaksaraei A. Imipenem-resistant strains carry metallo-beta-lactamase gene bla(VIM) in a level I Iranian burn hospital. Burns 2009.
12. Mehrgan H, Rahbar M. Prevalence of extended- spectrum beta-lactamase-producing Escherichia coli in a tertiary care hospital in Tehran, Iran. Int J Antimicrob Agents 2008; 31: 147-151.
13. Khosravi AD, Mihani F. Detection of metallo-beta- lactamase-producing Pseudomonas aeruginosa strains isolated from burn patients in Ahwaz, Iran. Diagn Microbiol Infect Dis 2008; 60: 125-158.
14. Mansouri M, Ramazanzadeh R. Spread of Extended-Spectrum Beta-Lactamase Producing Escherichia coli Clinical Isolates in Sanandaj Hospitals. Asian Network for Scientific Information; 2009.
15. Vranes J, Marijan T, Bedenic B, Mlinaric-Dzepina A, Katic S, Kalenic S. Clonal dissemination of highly virulent extended-spectrum beta-lactamase- producing Escherichia coli strains isolated from the urine of non-hospitalised patients in Zagreb region. Int J Antimicrob Agents 2008; 31 Suppl 1: S19-S24.
16. Aktaş Z, Gönüllü N, Schneider I, Bal C, Bauernfeind A. Detection of CTX-M-15 type extended spectrum beta-lactamase in an Escherichia coli strain isolated from the urine sample of a hospitalized patient. Mikrobiyol Bul 2005; 39: 421-429 (in Turkish).
17. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests Wayne, PA: Approved Standard M2-A7. 2000.
18. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta- lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-878.
19. Yao F, Qian Y, Chen S, Wang P, Huang Y. Incidence of extended-spectrum beta-lactamases and characterization of ıntegrons in extended- spectrum beta-lactamase-producing Klebsiella pneumoniae ısolated in Shantou, China. Acta Biochim Biophys Sin (Shanghai) 2007; 39: 527- 532.
20. Bergogne-Berezin E. Guidelines on antimicrobial chemotherapy for prevention and treatment of infections in the intensive care unit. J Chemother 2001; 13: 134-149.
21. Akkoyun S, Kuloğlu F, Tokuç B. Etiologic agents and risk factors in nosocomial urinary tract infections. Mikrobiyol Bul 2008; 42: 245-254 (in Turkish).
22. Alcantar-Curiel D, Tinoco JC, Gayosso C, et al. Nosocomial bacteremia and urinary tract infections caused by extended-spectrum beta -lactamase- producing Klebsiella pneumoniae with plasmids carrying both SHV-5 and TLA-1 genes. Clin Infect Dis 2004; 38: 1067-1074.
23. Cormican M, Morris D, Corbett-Feeeney G, Flynn J. Extended spectrum beta-lactamase production and fluorquinolone resistance in pathogens associated with community acquired urinary tract infection. Diagn Microbiol Infect Dis 1998; 32: 317-319.
24. Ena J, Arjona F, Martinez-Peinado C, Lopez- Perezagua Mdel M, Amador C. Epidemiology of urinary tract infections caused by extended- spectrum beta-lactamase-producing Escherichia coli. Urology 2006; 68: 1169-1174.
25. Khurana S, Taneja N, Sharma M. Extended spectrum beta-lactamase mediated resistance in urinary tract isolates of family Enterobacteriaceae. Indian J Med Res 2002; 116: 145-149.
26. Lagace-Wiens PR, Nichol KA, Nicolle LE, et al. Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta- lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate. J Antimicrob Chemother 2006; 57: 1262-1263.
27. Ozden M, Kalkan A, Demirdag K, Kilic SS, Ozdarendeli A. Ciprofloxacin and co-trimoxazole resistance and extended spectrum beta-lactamase production in Escherichia coli strains isolated from urinary tract infections. Int J Antimicrob Agents 2003; 21: 492-493.
28. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase- producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007; 29: 62-65.
29. Nakhjavani FA, Mirsalehian A, Hamidian M, Kazemi B, Mirafshar M, Jabalameli F. Antimicrobial susceptibility testing for Escherichia coli strains to fluoroquinolones, in urinary tract ınfections. Iranian J public Heath 2007; 1: 89-92.
30. Akbari-Nakhjavani F, Mirsalehian A, Hamidian M, et al. Antimicrobial susceptibility testing of Escherichia coli strains isolated from urinary tract infections to fluoroquinolones and detection of gyrA mutations in resistant strains Daru, Journal of Faculty of Pharmacy Tehran University of Medical Sciences 2007; 2: 94-99.
31. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-951.
32. Hosseini-Mazinani SM, Eftekhar F, Milani M, Ghandili S. Characterization of beta-lactamases from urinary isolates of Escherichia coli in Tehran. Iran Biomed J 2007; 11: 95-99.
33. Hirakata Y, Matsuda J, Miyazaki Y, et al. Regional variation in the prevalence of extended- spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis 2005; 52: 323-329.
34. Jeong SH, Bae IK, Lee JH, et al. Molecular characterization of extended-spectrum beta- lactamases produced by clinical isolates of Klebsiella pneumoniae and Escherichia coli from a Korean nationwide survey. J Clin Microbiol 2004; 42: 2902-2906.
35. Liu G, Ling BD, Zeng Y, Lin L, Xie YE, Lei J. Molecular characterization of extended-spectrum beta-lactamases produced by clinical Isolates of Enterobacter cloacae from a Teaching Hospital in China. Jpn J Infect Dis 2008; 61: 286-289.
36. Ryoo NH, Kim EC, Hong SG, et al. Dissemination of SHV-12 and CTX-M-type extended-spectrum beta-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae and emergence of GES-3 in Korea. J Antimicrob Chemother 2005; 56: 698-702.